This study is for patients with metastatic colorectal cancer (CRC), which means the cancer has spread beyond the colon or rectum. The trial compares two treatments: Ivonescimab or Bevacizumab, each combined with a chemotherapy regimen called mFOLFOX6. mFOLFOX6 includes three drugs: Oxaliplatin, Leucovorin, and 5-Fluorouracil, given to help stop cancer cells from growing. Patients will not know which treatment they get, as the study is double-blind. It's also randomized, meaning patients are randomly assigned to a treatment group.

• Participants will receive treatment every two weeks (Q2W) for up to 8 cycles, followed by maintenance treatment for up to 2 years.
• To join, you must have metastatic CRC, with no prior treatments for it, and expect to live at least 6 more months.
• About 600 participants will join, and the study will occur in multiple locations.